Clinical application of targeted therapy (BRAF inhibitors with or without MEK inhibitors) and immunotherapy (PD-1 inhibitors and CTLA-4 inhibitors) improve the survival of patients with unresectable melanoma, but the principal therapy for localized melanoma is surgical eradication [3,4]. The gene discussed is CTLA4; the disease is melanoma.